Please note: Most, if not all, of the articles published at this website were completed by Chat GPT (chat.openai.com) and/or copied and possibly remixed from other websites or Feedzy or WPeMatico or RSS Aggregrator or WP RSS Aggregrator. No copyright infringement is intended. If there are any copyright issues, please contact: bicycledays@yahoo.com.
Synthetic intelligence can discover hidden indicators in knowledge throughout healthcare, and corporations like Nvidia are leaning into what this may imply. For instance, it introduced two dozen new AI-powered instruments final week for areas together with biotechnology and drug discovery. And Nvidia shouldn’t be alone.
Century Well being is a brand new startup additionally getting in on the motion. It’s making use of AI to medical knowledge to uncover new purposes for medication. It’s working with pharmaceutical corporations and researchers, initially at Yale and UC San Diego, to establish and commercialize the following breakthrough for ailments, like Alzheimer’s, that have an effect on tens of tens of millions of sufferers.
The mission is a private one for Century Well being’s co-founder and CEO, Vish Srivastava. He watched his grandfather’s Alzheimer’s get to the purpose the place he didn’t acknowledge Srivastava anymore.
“That despatched me down a rabbit gap,” mentioned Srivastava, whose background is in healthcare product improvement and knowledge. “One of many largest points round innovation for brand new therapies is environment friendly entry to good affected person knowledge. That is now solely doable due to generative AI. That knowledge sat round for many years as a result of it takes guide effort to normalize and extract perception from it.”
That’s when he teamed up with pal Sanjay Hariharan, a knowledge scientist and utilized AI engineer, to type Century Well being. They constructed a platform to extract that hidden knowledge and combination it. Researchers and pharma corporations subscribe to the platform and might then use that knowledge on accredited medication; to broaden to new medication; or to seek out insights to broaden entry to medication which have already been accredited.
The last word purpose is accelerating entry to therapies, Srivastava mentioned.
“Drug improvement is massively costly, and on common, takes $1 billion to $2 billion to develop a brand new drug,” he mentioned. “From the pharma firm’s perspective, when their drug is now accredited, the mission is to get it to sufferers as rapidly as doable. For us, that additionally means as affordably as doable with entry to good real-world knowledge.”
Now with $2 million pre-seed funding, Century Well being will run three to 5 pilots over the following a number of months. The purpose is to validate the preliminary expertise that collects the info and, most significantly, to see the impression the insights from these knowledge units can deliver, Srivastava mentioned.
He sees these pilots as design partnerships and a approach to get suggestions on the advantages of medicine, for instance, which affected person subpopulation may be underrepresented. Along with the validated expertise, one other milestone might be to safe early income from the pilots, which Century Well being can leverage to go after one other spherical of enterprise capital.
The funding was led by 2048 Ventures with participation from LifeX, All over the place, Alumni Ventures and a gaggle of angel buyers, together with Datavant founder Travis Might and Evidation founder and CEO Christine Lemke.
Alex Iskold, managing accomplice of 2048 Ventures, mentioned in a press release, “At 2048 Ventures now we have a robust thesis round real-time knowledge, in healthcare and past. Vish and Sanjay have a imaginative and prescient to leverage AI and actual world affected person knowledge to unlock a greater suggestions loop and finally sooner and extra environment friendly drug improvement and commercialization.”
